Keywords
methylene blue
sildenafil citrate
mice
L-NAME
L-arginine hydrochloride
Abstract
The tendency of a psychostimulant to increase locomotion in rodents is considered to be associated with its addictive properties. Mephedrone, one of the most popular psychoactive substances used recreationally, is known to enhance locomotor activity in mice, but little is known about the potential development of tolerance to its central effects. In the present study, we decided to evaluate the possible involvement of the L-arginine-NO-cGMP pathway in the development of tolerance to mephedrone-induced hyperlocomotion. Experiments were performed on adult male Albino Swiss mice, and the locomotor activity was measured automatically. Our work indicated that a 5-day administration of L-NAME (25 or 50 mg/kg/day), methylene blue (5 or 10 mg/kg/day), and L-arginine hydrochloride (i.e., 250 mg/kg/day) prevented the development of tolerance to mephedrone-induced (5 mg/kg/day) hyperlocomotion, whereas treatment with L-arginine hydrochloride at a dose of 125 mg/kg/day potentiated the development of tolerance to this central effect of mephedrone. Summarizing, our data revealed that the L-arginine-NO-cGMP pathway contributes to the development of tolerance to mephedrone’s central effects since inhibition of this signalling via blocking of NOS or NO-stimulated sGC prevented the development of tolerance to mephedrone-induced hyperlocomotion. As for cGMP-regulated phosphodiesterases, most probably they are not involved in these mechanisms.
References
1. Baumann MH, Ayestas MA, Jr., Partilla JS, Sink JR, Shulgin AT, Daley PF, et al. The designer methcathinone analogs, mephedrone and methylone, are substrates for monoamine transporters in brain tissue. Neuropsychopharmacol. 2012;37:1192-203.
2. Lopez-Arnau R, Martinez-Clemente J, Pubill D, Escubedo E, Camarasa J. Comparative neuropharmacology of three psychostimu-lant cathinone derivatives: butylone, mephedrone and methylone. Br J Pharmacol. 2012;167:407-20.
3. Martinez-Clemente J, Escubedo E, Pubill D, Camarasa J. Interaction of mephedrone with dopamine and serotonin targets in rats. Eur Neuropsychopharmacol. 2012;22:231-6.
4. Nagai F, Nonaka R, Satoh Hisashi KK. The effects of non-medically used psychoactive drugs on monoamine neurotransmission in rat brain. Eur J Pharmacol. 2007;559:132-7.
5. Kehr J, Ichinose F, Yoshitake S, Goiny M, Sievertsson T, Nyberg F, et al. Mephedrone, compared with MDMA (ecstasy) and amphetamine, rapidly increases both dopamine and 5-HT levels in nucleus accumbens of awake rats. Br J Pharmacol. 2011;164:1949-58.
6. Hadlock GC, Webb KM, McFadden LM, Chu PW, Ellis JD, Allen SC, et al. 4-Methylmethcathinone (mephedrone): neuropharmacological effects of a designer stimulant of abuse. J Pharmacol Exp Ther. 2011; 339:530-6.
7. Eshleman AJ, Wolfrum KM, Hatfield MG, Johnson RA, Murphy KV, Janowsky A. Substituted methcathinones differ in transporter and receptor interactions. Biochem Pharmacol. 2013;85:1803-15.
8. Angoa-Perez M, Kane MJ, Francescutti DM, Sykes KE, Shah MM, Mohammed AM, et al. Mephedrone, an abused psychoactive component of ‘bath salts’ and methamphetamine congener, does not cause neurotoxicity to dopamine nerve endings of the striatum. J Neurochem. 2012;120:1097-107.
9. Simmler LD, Buser TA, Donzelli M, Schramm Y, Dieu LH, Huwyler J, et al. Pharmacological characterization of designer cathinones in vitro. Br J Pharmacol. 2013;168:458-70.
10. Papaseit E, Moltó J, Muga R, Torrens M, de la Torre R, Farré M. Clinical pharmacology of the synthetic cathinone mephedrone. Curr Top Behav Neurosci. 2017;32:313-31.
11. Lisek R, Xu W, Yuvasheva E, Chiu YT, Reitz AB, Liu-Chen LY, et al. Mephedrone (‘bath salt’) elicits conditioned place preference and dopamine-sensitive motor activation. Drug Alcohol Depend. 2012;126:257-62.
12. Motbey CP, Hunt GE, Bowen MT, Artiss S, McGregor IS. Mephedrone (4-methylmethcathinone, ‘meow’): acute behavioural effects and distribution of Fos expression in adolescent rats. Addict Biol. 2012;17:409-22.
13. Shortall SE, Spicer CH, Ebling FJ, Green AR, Fone KC, King MV. Contribution of serotonin and dopamine to changes in core body temperature and locomotor activity in rats following repeated administration of mephedrone. Addict Biol. 2016;21:1127-39.
14. Gregg RA, Tallarida CS, Reitz A, McCurdy C, Rawls SM. Mephedrone (4-methylmethcathinone), a principal constituent of psychoactive bath salts, produces behavioral sensitization in rats. Drug Alcohol Depend. 2013;133:746-50.
15. Gregg RA, Baumann MH, Partilla JS, Bonano JS, Vouga A, Tallarida CS, et al. Stereochemistry of mephedrone neuropharmacology: enantiomer-specific behavioural and neurochemical effects in rats. Br J Pharmacol. 2015;172:883-94.
16. Calabrese EJ. Addiction and dose response: the psychomotor stimulant theory of addiction reveals that hormetic dose responses are dominant. Crit Rev Toxicol. 2008;38:599-617.
17. Ball K, Slane M. Tolerance to the locomotor-activating effects of 3,4-methylenedioxymethamphetamine (MDMA) predicts escalation of MDMA self-administration and cue-induced reinstatement of MDMA seeking in rats. Behav Brain Res. 2014, 274:143-8.
18. Jones K, Brennan KA, Colussi-Mas J, Schenk S. Tolerance to 3,4-methylenedioxymethamphetamine is associated with impaired serotonin release. Addict Biol. 2010;15:289-98.
19. Torres Valladares D, Kudumala S, Hossain M, Carvelli L. Caenorhabditis elegans as an in vivo model to assess amphetamine tolerance. Brain Behav Evol. 2021.
20. Siciliano CA, Saha K, Calipari ES, Fordahl SC, Chen R, Khoshbouei H, Jones SR. Amphetamine reverses escalated cocaine intake via restoration of dopamine transporter conformation. J Neurosci. 2018;38:484-97.
21. Wabe NS. Chemistry, pharmacology, and toxicology of khat (catha edulis forsk): a review. Addict Health. 2011;3:137-49.
22. Goldsmith R, Pachhain S, Choudhury SR, Phuntumart V, Larsen R, Sprague JE. Gender differences in tolerance to the hyperthermia mediated by the synthetic cathinone methylone. Temperature (Austin). 2019;6:334-40.
23. Atehortua-Martinez LA, Masniere C, Campolongo P, Chasseigneaux S, Callebert J, Zwergel C, et al. Acute and chronic neurobehavioral effects of the designer drug and bath salt constituent 3,4-methylenedioxypyrovalerone in the rat. J Psychopharmacol. 2019;33:392-405.
24. Schechter MD. Dopaminergic nature of acute cathine tolerance. Pharmacol Biochem Behav. 1990;36:817-20.
25. Lopez-Arnau R, Martinez-Clemente J, Rodrigo T, Pubill D, Camarasa J, Escubedo E. Neuronal changes and oxidative stress in adolescent rats after repeated exposure to mephedrone. Toxicol Appl Pharmacol. 2015;286:27-35.
26. Suyama JA, Banks ML, Negus SS. Effects of repeated treatment with methcathinone, mephedrone, and fenfluramine on intracranial self-stimulation in rats. Psychopharmacology (Berl). 2019;236:1057-66.
27. Winstock A, Mitcheson L, Ramsey J, Davies S, Puchnarewicz M, Marsden J. Mephedrone: use, subjective effects and health risks. Addiction. 2011;106:1991-6.
28. Rácz J, Csák R, Faragó R, Vadász V. The phenomenon of drug change in the interviews with injecting drug users. Psychiatr Hung. 2012;27:29-47.
29. Nencini P, Johanson CE, Schuster CR. Sensitization to kappa opioid mechanisms associated with tolerance to the anorectic effects of cathinone. J Pharmacol Exp Ther. 1988;245:147-54.
30. Bruckdorfer R. The basics about nitric oxide. Mol Aspects Med. 2005;26:3-31.
31. Kourosh-Arami M, Hosseini N, Mohsenzadegan M, Komaki A, Joghataei MT. Neurophysiologic implications of neuronal nitric oxide synthase. Rev Neurosci. 2020;31:617-36.
32. Talarek S, Listos J, Fidecka S. Role of nitric oxide in the development of tolerance to diazepam-induced motor impairment in mice. Pharmacol Rep. 2008;60:475-82.
33. Talarek S, Listos J, Orzelska-Gorka J, Jakobczuk M, Kotlinska J, Biala G. The Importance of L-Arginine:NO:cGMP pathway in tolerance to Flunitrazepam in mice. Neurotox Res. 2017;31:309-16.
34. Mansouri MT, Naghizadeh B, Ghorbanzadeh B, Alboghobeish S, Amirgholami N, Houshmand G, et al. Venlafaxine prevents morphine antinociceptive tolerance: The role of neuroinflammation and the l-arginine-nitric oxide pathway. Exp Neurol. 2017;303:134-41.
35. Ozdemir E, Bagcivan I, Durmus N, Altun A, Gursoy S. The nitric oxide-cGMP signaling pathway plays a significant role in tolerance to the analgesic effect of morphine. Can J Physiol Pharmacol. 2011;89:89-95.
36. Talarek S, Listos J, Orzelska-Gorka J, Serefko A, Kotlinska J. NMDA Receptors and NO:cGMP Signaling Pathway Mediate the Diazepam-Induced Sensitization to Withdrawal Signs in Mice. Neurotox Res. 2018;33:422-32.
37. Shortall SE, Macerola AE, Swaby RT, Jayson R, Korsah C, Pillidge KE, et al. Behavioural and neurochemical comparison of chronic intermittent cathinone, mephedrone and MDMA administration to the rat. Eur Neuropsychopharmacol. 2013;23:1085-95.
38. Nguyen JD, Aarde SM, Cole M, Vandewater SA, Grant Y, Taffe MA. Locomotor Stimulant and Rewarding Effects of Inhaling Methamphetamine, MDPV, and Mephedrone via Electronic Cigarette-Type Technology. Neuropsychopharmacol. 2016;41:2759-71.
39. Peper A. A theory of drug tolerance and dependence I: a conceptual analysis. J Theor Biol. 2004;229:477-90.
40. Pantano F, Tittarelli R, Mannocchi G, Pacifici R, di LA, Busardo FP, et al. Neurotoxicity Induced by Mephedrone: An up-to-date Review. Curr Neuropharmacol. 2017;15:738-49.
41. Martinez-Clemente J, Lopez-Arnau R, Abad S, Pubill D, Escubedo E, Camarasa J. Dose and time-dependent selective neurotoxicity induced by mephedrone in mice. PLoS One. 2014;9:e99002.
42. Trabace L, Kendrick KM. Nitric oxide can differentially modulate striatal neurotransmitter concentrations via soluble guanylate cyclase and peroxynitrite formation. J Neurochem. 2000;75:1664-74.
43. Celik T, Zagli U, Kayir H, Uzbay IT. Nitric oxide synthase inhibition blocks amphetamine-induced locomotor activity in mice. Drug Alcohol Depend. 1999;56:109-13.
44. Abekawa T, Ohmori T, Koyama T. Effect of NO synthase inhibition on behavioral changes induced by a single administration of methamphetamine. Brain Res. 1994;666:147-50.
45. Kim HS, Park WK. Nitric oxide mediation of cocaine-induced dopaminergic behaviors: ambulation-accelerating activity, reverse tolerance and conditioned place preference in mice. J Pharmacol Exp Ther. 1995;275:551-7.
46. Itzhak Y, Martin JL. Effect of the neuronal nitric oxide synthase inhibitor 7-nitroindazole on methylphenidate-induced hyperlocomotion in mice. Behav Pharmacol. 2002;13:81-6.
47. Salter M. Determination of the flux control coefficient of nitric oxide synthase for nitric oxide synthesis in discrete brain regions in vivo. J Theor Biol. 1996;182:449-52.
48. Uzbay IT, Oglesby MW. Nitric oxide and substance dependence. Neurosci Biobehav Rev. 2001;25:43-52.
49. Heinzen EL, Pollack GM. Pharmacodynamics of morphine-induced neuronal nitric oxide production and antinociceptive tolerance development. Brain Res. 2004;1023:175-84.
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 3.0 Unported License.
Copyright (c) 2023 Authors